This white paper analyzes India’s growing role as a global destination for obesity clinical research. It highlights the country’s large, treatment-naïve patient population, evolving regulatory framework, and increasing adoption of digital and decentralized trial capabilities. The report discusses operational efficiencies, cost advantages, and improved regulatory transparency that support faster trial execution. It also addresses considerations around patient diversity, data quality, and global compliance. By outlining strategic implications for sponsors, the paper positions India as a scalable, high-value option for conducting complex obesity trials aligned with international standards.

Join for free to read